Payment overview · 2025
General Payments
$26,791.66
157 reported records · 18 companies
Healthcare provider profile · identity verified
Mark Christian Bieniarz, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · ALBUQUERQUE, NM · NPI 1174776868
Verified facts
What the public records show
CMS Open Payments records show Mark Christian Bieniarz, MD received $26,791.66 in general payments during 2025 across 157 reported records.
Edwards Lifesciences Corporation accounted for 83.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Brilinta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $22,484.34 | 83.9% | 74 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $1,182.65 | 4.4% | 20 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,130.24 | 4.2% | 13 | 2025 |
| Ancora Heart, Inc. | Unresolved — no canonical attribution shown | $931.63 | 3.5% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $464.33 | 1.7% | 18 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $110.77 | 0.4% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$110.72 | 0.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $93.70 | 0.3% | 6 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $53.06 | 0.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.58 | 0.1% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $37.36 | 0.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $31.41 | 0.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.06 | 0.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.48 | 0.1% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $20.76 | 0.1% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $19.66 | 0.1% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $15.06 | 0.1% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $13.85 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $14,531.25 | 2 |
| Travel and Lodging | $6,547.31 | 31 |
| Food and Beverage | $5,713.10 | 124 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $13,906.25 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $2,739.39 | 34 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $980.78 | 9 | 2025 |
Source payment records
|
|||||
| AccuCinch Normalized: accucinch |
Device | Ancora Heart, Inc. | $931.63 | 4 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $625.00 | 1 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $218.16 | 4 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $141.25 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $118.31 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $110.77 | 5 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $99.98 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $96.54 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $93.70 | 6 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $91.16 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $58.50 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $53.06 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| PERCLOT Normalized: perclot |
Device | Baxter Healthcare | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $31.41 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| 2ND GEN CENTRIMAG PRIMARY CONSOLE Normalized: 2nd gen centrimag primary console |
Device | Abbott Laboratories | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| Rotablator Rotational Atherectomy System Console Kit Normalized: rotablator rotational atherectomy system console kit |
Device | Boston Scientific Corporation | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| GUIDELINER Normalized: guideliner |
Device | Teleflex LLC | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| CLEVIPREX Normalized: cleviprex |
Drug | Chiesi USA, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $6.50 | 1 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $5.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
39 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
103 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 763 | 255 |
| Amlodipine Besylate | Amlodipine Besylate | 539 | 176 |
| Carvedilol | Carvedilol | 532 | 166 |
| Atorvastatin Calcium | Atorvastatin Calcium | 470 | 152 |
| Losartan Potassium | Losartan Potassium | 375 | 138 |
| Irbesartan | Irbesartan | 348 | 114 |
| Eliquis | Apixaban | 334 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 319 | 101 |
| Nebivolol Hcl | Nebivolol Hcl | 263 | 93 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 262 | 81 |
| Clopidogrel | Clopidogrel Bisulfate | 245 | 99 |
| Ezetimibe | Ezetimibe | 192 | 66 |
| Lisinopril | Lisinopril | 167 | 58 |
| Furosemide | Furosemide | 151 | 61 |
| Spironolactone | Spironolactone | 129 | 46 |
| Potassium Chloride | Potassium Chloride | 112 | 41 |
| Repatha Sureclick | Evolocumab | 106 | 23 |
| Entresto | Sacubitril/Valsartan | 103 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 90 | 28 |
| Valsartan | Valsartan | 80 | 30 |
| Amoxicillin | Amoxicillin | 79 | 48 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 67 | 25 |
| Chlorthalidone | Chlorthalidone | 61 | 24 |
| Xarelto | Rivaroxaban | 56 | 20 |
| Repatha Pushtronex | Evolocumab | 54 | 13 |
| Ranolazine Er | Ranolazine | 53 | 20 |
| Nitroglycerin | Nitroglycerin | 52 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 17 |
| Mupirocin | Mupirocin | 46 | 44 |
| Brilinta | Ticagrelor | 39 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 27 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 24 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | 12 |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 17 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $26,791.66 · 157 records | Edwards Lifesciences Corporation | 2ND GEN CENTRIMAG PRIMARY CONSOLE, ACCOLADE SR, AVVIGO Guidance System, AccuCinch, CLEVIPREX, COREVALVE EVOLUT R, COROFLOW, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), EVOQUE, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, GUIDELINER, General - Brady, General - Therapies, INSPIRE, KENGREAL, LEQVIO, LifeVest, NAVITOR, OPSUMIT, OPTIS, PERCLOT, REPATHA, Rotablator Rotational Atherectomy System Console Kit, SAPIEN 3 Ultra RESILIA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRICLIP, VERQUVO, WATCHMAN, WATCHMAN FLX, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error